Navigation Links
Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
Date:5/9/2008

cancer drugs from Australia's research base. It will undertake responsibility for the further development of Cytopia's early compounds towards a preclinical candidate compound which is capable of further development into and through clinical trials.

"We are delighted to be embarking on a collaboration of this type with a leading Australian drug development company such as Cytopia," said Tony Evans, CEO of Cancer Therapeutics. "Our company was founded with the vision to aid in the further development of Australian biotechnology industry by applying drug discovery and development capabilities to early research findings and take on projects that are in the high risk category from commercial organizations or academic institutions to unlock their commercial potential."

Cytopia's advanced anti-cancer drug is being tested in four clinical programs covering oral and IV doses in Phase I and Phase II level studies. Trials are advanced for both oral and injectable vascular disrupting agents (VDAs), multiple myeloma and an aggressive brain tumor glioblastoma multiforme (GBM).

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules with an improved therapeutic profile for the treatment of cancer. Cytopia's lead compound, CYT997, is currently in Phase II clinical trials.

Website: http://www.cytopia.com.au

About Cancer Therapeutics

Cancer Therapeutics CRC Pty Ltd has been formed through a collaboration between a number of Australia's leading research institutions and commercial organizations for the purposes of cancer drug discovery and development. It is funded under the Australian Government's CRC scheme. The objective of the Compa
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
(Date:9/1/2015)... 1, 2015 Emerus Holdings, a national ... inpatient and diagnostic care in partnership with leading ... definitive agreement to receive a strategic investment from ... leading health care investment firm. Emerus ... acute episodic and ambulatory clinical services to communities ...
(Date:9/1/2015)... --  Alpha Imaging LLC , a leading distributor of advanced medical ... that they have been awarded exclusive rights to represent the complete ... new territory supplements Alpha Imaging,s existing Shimadzu sales and service responsibilities ... , Indiana , Pennsylvania , ... West Virginia , Delaware and ...
Breaking Medicine Technology:Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3Alpha Imaging Expands Shimadzu Territory 2
... at Brigham and Women,s,Hospital found that patients taking cannabinoid ... were unrelated to relief from their pain,symptoms. Results ... the addictive,potential of this class of pain medicine, were ... Annual Meeting. , In the ...
... The Netherlands, January 28 ,Amsterdam Molecular Therapeutics ... of,human gene therapy, announced today during the ... showing that one treatment of its lead ... and clinically important,lowering of the incidence of ...
Cached Medicine Technology:Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief 2AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly 2AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly 3
(Date:9/1/2015)... ... September 01, 2015 , ... Horizon Blue Cross Blue Shield of New Jersey ... in the LATINA Style 50 Report that recognizes companies that provide the best career ... Horizon BCBSNJ climbs from number 24 to 21 of the 50 Best Companies for ...
(Date:9/1/2015)... Eagan, Minnesota (PRWEB) , ... September 01, 2015 ... ... covered health care delivery options, Blue Cross and Blue Shield of Minnesota (Blue ... starting in 2016. , Based in San Francisco, Doctor On Demand provides ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, TX ... , an innovative vaginal health laser procedure that prevents and resolves dryness in ... atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse and ...
(Date:9/1/2015)... Burlington, MA (PRWEB) , ... September 01, 2015 ... ... for remote real-time monitoring and analysis of pet vital signs and activity, today ... Cornerstone is one of the most popular and widely-adopted veterinary hospital Practice Management ...
(Date:9/1/2015)... ... ... Royal River Natural Foods, a locally-owned independent natural health store in Freeport, ... and found that, among those who had a stroke, people who used multivitamins survived ... the September 2015 issue of “Natural Insights for Well Being,” which Royal River Natural ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... 30% in 2007, ... to Millennium Research Group, WALTHAM, Mass., Feb. 25 ... or equal to 3.0 mm),dental implants are becoming increasingly popular ... faster rate than those of regular-diameter,(> 3.0 mm) dental implants., ...
... anxious about their skin condition say they are less likely ... at the University of Bath (UK). , The study, published ... middle-aged adults recruited from a national acne support group. , ... participate in sport or exercise, acne sufferers who perceived their ...
... Aware,s AccuRad client/server software suite enables remote browser-based, ... bandwidth-constrained network, BEDFORD, Mass., Feb. 25 ... and biometrics software, today,announced it will showcase the ... the 2008 Annual HIMSS Conference & Exhibition. HIMSS08,is ...
... Inc. (OTC Bulletin,Board: IAGX), announced today that the ... Committee has selected Celadrin(R),Topical Cream as its Official ... provide the best medical care for the athletes ... has expanded its goal to provide the most,advanced ...
... 25, 2008 A vaginal microbicide that incorporates an antiretroviral ... safe for sexually active HIV-negative women to use every day ... of tenofovir topical gel. Moreover, most of the women who ... States adhered to a regimen involving either daily or sex-dependent ...
... (Nasdaq:,LCAV), a leading provider of laser vision correction services ... vision center in Des,Moines, Iowa. This marks the 74th ... LasikPlus vision center in the state of Iowa.,LasikPlus vision ... markets., Similar to other LasikPlus vision centers throughout ...
Cached Medicine News:Health News:Small-Diameter Dental Implants Increasingly Popular In the US 2Health News:Acne may prevent people from participating in sport and exercise, says research 2Health News:Aware, Inc. to Demonstrate Groundbreaking Medical Imaging Streaming Solution at HIMSS08 2Health News:Aware, Inc. to Demonstrate Groundbreaking Medical Imaging Streaming Solution at HIMSS08 3Health News:Aware, Inc. to Demonstrate Groundbreaking Medical Imaging Streaming Solution at HIMSS08 4Health News:Aware, Inc. to Demonstrate Groundbreaking Medical Imaging Streaming Solution at HIMSS08 5Health News:International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as it's First and Only Official Joint and Muscle Topical Cream 2Health News:International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as it's First and Only Official Joint and Muscle Topical Cream 3Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 2Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 3Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 4Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 5Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 6Health News:LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: